MedTrace Logo

Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft

NCT03280290 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-09-12

No results posted yet for this study

Summary

This is a preclinical study prior to the establishment of a cell therapy protocol applicable to humans.

The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by partial selective depletion of CD4 + CCR7 + graft to less than 50 % of CD4 + totals. To test the alloreactivity of donor T lymphocytes.

Conditions

  • Acute Myeloblastic Leukemia

Interventions

BIOLOGICAL

blood

assessment pre-donation of hematopoietic stem cells (blood sample)

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • YAKOUB-AGHA IBRAHIM, Professor · CHRU de Lille

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-20
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280290 on ClinicalTrials.gov